GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Shares Buyback Ratio %

Shield Therapeutics (LSE:STX) Shares Buyback Ratio % : -220.39 (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Shield Therapeutics's current shares buyback ratio was -220.39%.


Shield Therapeutics Shares Buyback Ratio % Historical Data

The historical data trend for Shield Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Shares Buyback Ratio % Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only - -0.66 -0.37 -83.55 -16.72

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.54 -0.01 -0.14 -16.55 -174.89

Shield Therapeutics Shares Buyback Ratio % Calculation

Shield Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2021 ) - Shares Outstanding (EOP) (A: Dec. 2022 )) / Shares Outstanding (EOP) (A: Dec. 2021 )
=(222.235 - 259.388) / 222.235
=-16.72%

Shield Therapeutics's Shares Buyback Ratio for the quarter that ended in Jun. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Jun. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(259.388 - 713.036) / 259.388
=-174.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.